Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant bivalent HPV16/18 vaccine (yeast) in healthy females 9-45 years
CTR20130604Phase 2Completed
- Sponsor
- Shanghai Zerun Biotechnology Co., Ltd.
- Start
- Sep 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Walrinvax in HPV16 infection (HPV16), human papillomavirus infection type 18, cervical intraepithelial neoplasia (CIN), Cervical Cancer (CC), sponsored by Shanghai Zerun Biotechnology Co., Ltd.. Started Sep 2014; status: completed.
02
Drugs
Walrinvax
03
Conditions
HPV16 infection (HPV16)human papillomavirus infection type 18cervical intraepithelial neoplasia (CIN)Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20130604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130604.